Daptomycin Compared to Vancomycin for the Treatment of Osteomyelitis: A Single-Center, Retrospective Cohort Study

Clinical Therapeutics

Volumn 34, Issue 7, 2012, Pages 1521-1527

  Moenster, Ryan P ^a   Linneman, Travis W ^a   Finnegan, Patrick M ^b   McDonald, Jay R ^b  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Daptomycin; Long term antibiotics; Osteomyelitis; Vancomycin

Indexed keywords

CREATINE KINASE; DAPTOMYCIN; VANCOMYCIN;

ADULT; ARTICLE; CHI SQUARE TEST; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER; CONTROLLED STUDY; DIABETES MELLITUS; DRUG TOLERABILITY; FOLLOW UP; HUMAN; NEUTROPHIL COUNT; OSTEOMYELITIS; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; RECURRENCE RISK; RECURRENT DISEASE; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; COHORT STUDIES; DAPTOMYCIN; FOLLOW-UP STUDIES; HOSPITALS, VETERANS; HUMANS; MALE; MIDDLE AGED; OSTEOMYELITIS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84863825777     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.06.013     Document Type: Article

References (17)

1. Lipsky B.A., Berendt A.R., Deery H.G., et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004, 39:885-910.
2. Lamp K.C., Fridrich L.V., Mendez-Vigo L., Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med 2007, 120:S13-S20.
3. Rolston K.V., Segreti J. Daptomycin: an important addition to the management of gram-positive infections. Am J Med 2007, 120:S1-S3.
4. Finney M.S., Crank C.W., Segreti J. Use of daptomycin to treat drug-resistant gram-positive bone and joint infections. Curr Med Res Opin 2005, 21:1923-1926.
5. Rybak M., Lomaestro B., Rotschafer J.C., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Disease Pharmacists. Am J Health-Syst Pharm 2009, 66:82-98.
6. Cubicin (daptomycin) [package insert] 2010, Cubist Pharmaceuticals, Inc, Lexington, Mass.
7. Kosmidis C., Levine D.P. Daptomycin: pharmacology and clinical use. Expert Opin Pharmacother 2010, 11:615-625.
8. Livermore D. Future directions with daptomycin. J Antimicrob Chemother 2008, 62(Suppl. 3):iii41-iii49.
9. Luu Q.N., Buxton T.B., Nelson D.R., Rissing J.P. Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin. Eur J Clin Microbiol Infect Dis 1989, 8:562-563.
10. Mader J.T., Adams K. Comparative evaluation of daptomycin and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother 1989, 33:689-692.
11. Lefebvre M., Jacqueline C., Amador G., et al. Efficacy of daptomycin combined with rifampicin for the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. Int J Antimicrob Agents 2010, 36:542-544.
12. Lalani T., Boucher H.W., Cosgrove S.E., et al. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteremia. J Antimicrob Chemother 2008, 61:177-182.
13. Fowler V.G., Boucher H.W., Corey G.R., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355:653-665.
14. Rolston K.V., Segreti J Lamp K.C., Friedrich L.V. Cubist outcomes registry and experience (CORE) methodology. Am J Med 2007, 120:S4-S5.
15. Oleson F.B., Berman C.L., Kirkpatrick J.B., et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000, 44:2948-2953.
16. Bhavnani S.M., Rubino C.M., Ambrose P.G., Drusano G.L. Daptomycin exposure and the probability of elevations in creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010, 50:1568-1574.
17. Moise P.A., Hershberger E., Amodio-Groton M.I., Lamp K.C. Safety and clinical outcomes when utilizing high-dose (> or = 8 mg/kg) daptomycin therapy. Ann Pharmacother 2009, 43:1211-1219.